Roche reintroduces Susvimo for people with neovascular age-related macular degeneration

Roche has recently announced the reintroduction of Susvimo for intravitreal use via ocular implant for the treatment of people in the United States with neovascular or ‘wet’ age-related macular degeneration , following the end of a voluntary recall. The US Food and Drug Administration has approved a post-approval supplement to the Biologics License Application for Susvimo, reflecting component-level updates made to the ocular implant and refill needle.

“We are pleased to reintroduce Susvimo, a unique therapeutic approach shown to provide an effective alternative to regular eye injections by preserving vision with two refills per year in Phase III study patients with neovascular age-related macular degeneration,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Susvimo’s return to the retina community reflects our unwavering commitment to provide innovative retinal treatments, and lays the groundwork for future advancements.”

This Susvimo implant is technically surgically inserted into the eye during a one-time, outpatient procedure and is refilled once every six months using a specifically designed needle, which introduces a customised formulation of ranibizumab directly into the device. Susvimo was also approved by the FDA in 2021. 

 

---

---

Related Topics and Keywords

neovascular age-related macular degeneration, Roche, susvimo